# Redefining peptide therapeutics with semaglutide.

> PubMed lists PMID 38321235 in Nature chemistry as Journal Article, with publication-date metadata of 2024-02 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38321235-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-16
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38321235-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-38321235-semaglutide-v1.json
- Content SHA-256: `eb17c8dd4c3e0879f348a8807a2f025f59ffc8075900eadd02d9bbc4c81273a6`

## Claims and source pins

### Headline

Redefining peptide therapeutics with semaglutide. ([`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`](#source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d))

### Summary

PubMed lists PMID 38321235 in Nature chemistry as Journal Article, with publication-date metadata of 2024-02 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`](#source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d))

### Paragraph 1

PubMed lists PMID 38321235 in Nature chemistry as Journal Article, with publication-date metadata of 2024-02 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`](#source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`](#source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d))

## Sources

<a id="source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d"></a>
- **Redefining peptide therapeutics with semaglutide. · retained source version 1:2026-07-16:current:d50762aa8e1dd707937323c10f300b350d7d8ce3358d3b43571ebdf1bfa50120** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38321235/) (`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Redefining peptide therapeutics with semaglutide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-38321235-semaglutide-v1.json SHA-256: eb17c8dd4c3e0879f348a8807a2f025f59ffc8075900eadd02d9bbc4c81273a6.